Hospira Paclitaxel Concentrate for Solution for Infusion 100 mg/16.7 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira paclitaxel concentrate for solution for infusion 100 mg/16.7 ml vial

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: citric acid; peg-35 castor oil; ethanol absolute - paclitaxel is indicated, in combination with other drugs, for the treatment of certain diseases of the ovary, breast and lung, of kaposi's sarcoma linked to aids and where cellular growth is altered.

Hospira Paclitaxel for injection 100 mg/16.7 mL (6 mg/mL) Australia - English - Department of Health (Therapeutic Goods Administration)

hospira paclitaxel for injection 100 mg/16.7 ml (6 mg/ml)

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: citric acid; ethanol absolute; peg-35 castor oil - anzatax injection concentrate is indicated for the treatment of ovarian cancer, carcinomia of the breast, non-small lung cancer in the advanced stage and kaposi's sarcoma with aids

Hospira Paclitaxel Concentrate for Solution for Infusion 100 mg/16.7 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira paclitaxel concentrate for solution for infusion 100 mg/16.7 ml vial

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: peg-35 castor oil; citric acid; ethanol absolute - ovarian cancer: ??in first-line chemotherapy paclitaxel is indicated for the treatment of patients with advanced disease or a residual disease (>1 cm) after initial laparotomy, in combination with cisplatin. ??in second-line chemotherapy paclitaxel is indicated in the treatment of metastatic carcinoma of the ovary after failure of standard platinum based therapy. breast cancer: ??in the adjuvant setting, paclitaxel is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (ac) therapy. adjuvant treatment with paclitaxel should be regarded as an alternative to extended ac therapy. ??paclitaxel is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express human epidermal growth factor receptor 2 (her-2) at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. ??as a single agent, treatment of metastatic carcinoma of the breast in patients who have failed to respond adequately to standard treatment with anthracyclines or in whom anthracycline therapy has not been appropriate, or relapse within 6 months of adjuvant chemotherapy. advanced non-small cell lung cancer (nsclc): ??paclitaxel, in combination with cisplatin, is indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgical intervention and/or radiation therapy. aids-related kaposi?s sarcoma (ks): ??paclitaxel is indicated for the treatment of patients with advanced aids-related ks who have failed prior liposomal anthracycline therapy.

Hospira Paclitaxel Concentrate for Solution for Infusion 150 mg/25 mL Vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira paclitaxel concentrate for solution for infusion 150 mg/25 ml vial

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: peg-35 castor oil; citric acid; ethanol absolute - ovarian cancer: in first-line chemotherapy paclitaxel is indicated for the treatment of patients with advanced disease or a residual disease (>1 cm) after initial laparotomy, in combination with cisplatin. in second-line chemotherapy paclitaxel is indicated in the treatment of metastatic carcinoma of the ovary after failure of standard platinum based therapy. breast cancer: in the adjuvant setting, paclitaxel is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (ac) therapy. adjuvant treatment with paclitaxel should be regarded as an alternative to extended ac therapy. paclitaxel is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express human epidermal growth factor receptor 2 (her-2) at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. as a single agent, treatment of metastatic carcinoma of the breast in patients who have failed to respond adequately to standard treatment with anthracyclines or in whom anthracycline therapy has not been appropriate, or relapse within 6 months of adjuvant chemotherapy. advanced non-small cell lung cancer (nsclc): paclitaxel, in combination with cisplatin, is indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgical intervention and/or radiation therapy. aids-related kaposi's sarcoma (ks): paclitaxel is indicated for the treatment of patients with advanced aids-related ks who have failed prior liposomal anthracycline therapy.

Hospira Calcium Folinate Solution Injection 50 mg/5 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira calcium folinate solution injection 50 mg/5 ml vial

hospira australia pty ltd - calcium folinate, quantity: 10.8 mg/ml (equivalent: folinic acid, qty 10 mg/ml) - injection - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - calcium folinate is indicated a) to reduce the toxicity and neutralise the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. in cytotoxic therapy, this procedure is commonly known as ?calcium folinate rescue?; b) in combination with 5-fluorouracil in cytotoxic therapy.

Hospira Paclitaxel 150 mg/25 mL (6 mg/mL) Concentrate for Injection Vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira paclitaxel 150 mg/25 ml (6 mg/ml) concentrate for injection vial

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: citric acid; ethanol absolute; peg-35 castor oil - paclitaxel is indicated for the following: ovarian cancer first-line chemotherapy - treatment of advanced or residual stage ovarian cancer after initial laparotomy, in combination with cisplatin. second-line chemotherapy - treatment of metastatic carcinoma after failure of standard platinum based therapy. breast cancer treatment of node-positive breast cancer following athracycline and cyclophosphamide (ac) therapy. initial treatment of locally advanced or metastatic breast cancer, either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzamab in patients for whom an anthracycline is unsuitable. as a single agent, treatment of metastatic breast cancer when anthracycline therapy has not been appropriate. non-small cell lung cancer (nsclc) treatment in combination with cisplatin, of non-small cell lung cancer in patients unable to undergo radical surgery and/or radiation therapy. aids related kaposi's sarcoma treatment of patients with advanced aids related kaposi's sarcoma who have failed prior liposomal anthracycline therapy.

Hospira Vinorelbine Tartrate for injection vial 10 mg/1 mL Australia - English - Department of Health (Therapeutic Goods Administration)

hospira vinorelbine tartrate for injection vial 10 mg/1 ml

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. it is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Hospira VINORELBINE 10 mg/mL sterile concentrate 50 mg/5 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira vinorelbine 10 mg/ml sterile concentrate 50 mg/5 ml vial

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection - excipient ingredients: water for injections - non-small cell lung cancer (stage 3 or 4). as single agent to patients with metastatic breast cancer (stage 4), where treatment with anthracycline - and taxane containing chemotherapy has failed or is not appropriate.

Hospira Paclitaxel 6 mg/mL Concentrated Solution for Infusion, 150 mg/25 mL Vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira paclitaxel 6 mg/ml concentrated solution for infusion, 150 mg/25 ml vial

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: citric acid; ethanol absolute; peg-35 castor oil - paclitaxel is indicated, in combination with other drugs, for treating certain diseases of the ovary, breast and lung cancer, of kaposi's sarcoma linked to aids and where cellular growth is altered.

Hospira Vinorelbine 10 mg/1 mL Sterile Concentrate Vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira vinorelbine 10 mg/1 ml sterile concentrate vial

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine is indicated in the treatment of: - non-small cell lung cancer (stage 3 or 4) - as a single agent to patients with metastatic breast cancer (stage 4), where treatment with anthracycline- and taxane containing chemotherapy has failed or is not appropriate